Back to Newsroom

Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1

REGULATE-PCI Opened to “All Comers” PCI Population

BASKING RIDGE, N.J., April 2, 2014 /PRNewswire/ — Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the planned “all comers” percutaneous coronary intervention (PCI) patient population described in the trial protocol. REGULATE-PCI is Regado’s Phase 3 trial comparing REG1 to bivalirudin for superiority in reducing ischemic events in patients undergoing PCI, excluding those with ST-elevated myocardial infarction (STEMI). This development program was recently granted Fast Track designation by the FDA.